The present invention relates to the treatment or prevention of neurodegenerative polyglutamine diseases by the administration of effective amounts of L-methionine S-sulfoximine, L-ethionine S-sulfoximine, glufosinate and/or branched chain α-keto acids. In particular, the present invention relates to the treatment or prevention of Huntington's disease and other polyglutamine disorders caused by expanded genomic CAG nucleotides.
Treatment of polyglutamine disorders caused by expanding genomic CAG nucleotides